Sidra Medicine launches Casgevy in Qatar, the first CRISPR gene therapy for sickle cell and thalassemia, offering a potential ...
Cancer cells have ways to hide from the immune system, but there are some unique features on these dangerous cells that ...
DOHA: Sidra Medicine, a member of Qatar Foundation, announced that it has been qualified by Vertex Pharmaceuticals as one of ...
Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...
Scientists have developed ThermoCas9, a CRISPR enzyme capable of distinguishing cancer cells from healthy ones by reading DNA methylation patterns, potentially reducing off-target edits. In lab tests, ...
In light of increased interest in the capabilities of biotechnology worldwide, those who took part in the Youth DNA Forum in ...
Market Analysis And Outlook Report 2026-2036 - Emerging Gene Therapies, Lentiviral Vector-Based Therapies And CRISPR-Cas9 Gene Editing, Ignite Hope. Challenges include high costs and limited diagnosis ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the emphasis has been on its underlying mechanisms and nucleases. In contrast, ...
We'll know more about the company's medium-term prospects by the end of the year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results